Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-03-29
2004-08-17
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S049000, C514S616000, C536S028500, C424S009400, C424S078170, C564S152000, C564S153000, C564S159000
Reexamination Certificate
active
06777387
ABSTRACT:
TECHNICAL FIELD
The present invention relates to polymeric-based conjugates having increased therapeutic payloads. In particular, the invention relates to the use of extension moieties which increase the efficiency of the loading of active ingredients onto the polymeric carriers.
BACKGROUND OF THE INVENTION
Over the years, several methods of administering biologically-effective materials to mammals have been proposed. Many medicinal agents are available as water-soluble salts and can be included in pharmaceutical formulations relatively easily. Problems arise when the desired medicinal agent is either insoluble in aqueous fluids or is rapidly degraded in vivo. Alkaloids are often especially difficult to solubilize.
One way to solubilize medicinal agents is to include them as part of a soluble prodrug. Prodrugs include chemical derivatives of a biologically-active parent compound which, upon administration, eventually liberate the parent compound in vivo. Prodrugs allow the artisan to modify the onset and/or duration of action of an agent in vivo and can modify the transportation, distribution or solubility of a drug in the body. Furthermore, prodrug formulations often reduce the toxicity and/or otherwise overcome difficulties encountered when administering pharmaceutical preparations. Typical examples of prodrugs include organic phosphates or esters of alcohols or thioalcohols.
Prodrugs by definition are often biologically inert or substantially inactive forms of the parent or active compound. The rate of release of the active drug, i.e. the rate of hydrolysis, is influenced by several factors but especially by the type of bond joining the parent drug to the modifier. Care must be taken to avoid preparing prodrugs which are eliminated through the kidney or reticular endothelial system, etc. before a sufficient amount of hydrolysis of the parent compound occurs.
Incorporating a polymer as part of a prodrug system has been suggested to increase the circulating life of a drug. A brief overview of some previous work in the field is presented below.
Ohya, et al.,
J. Bioactive and Compatible Polymers
Vol. 10 January, 1995, 51-66, discloses doxorubicin-PEG conjugates which are prepared by linking the two substituents via various linkages including esters. The molecular weight of the PEG used, however, is only about 5,000 at most. Thus, the in vivo benefits are not fully realized because the conjugates are substantially excreted prior to sufficient linkage hydrolysis.
Commonly-assigned PCT publication WO96/23794 describes bis-conjugates in which one equivalent of the hydroxyl-containing drug is attached to each terminal of the linear polymer. In spite of this advance, techniques which would further increase the payload of the polymer have been sought.
In commonly-assigned U.S. patent application Ser. No. 09/293,624, filed Apr. 16, 1999, the disclosure of which is incorporated herein by reference, therapeutic polymeric conjugates with double or even greater therapeutic payloads are disclosed. Specifically, the polymers which are substantially linear, are designed to include multifunctional groups on both the alpha and omega terminus which are adapted for receiving up to four or more equivalents of a biologically active agent. Further work in this field has been done to address the problems which can occur when attempting to achieve complete or stochiometric loading of some active ingredients onto the multi-armed polymers. In particular situations, it has been found that it would be desirable to be able to provide more predictable and reproducible high degrees of loading. Such can be the case especially when steric hindrance or the molecular shape of the active ingredient reduces the likelihood of repeatable relatively complete loading of each multi-armed terminal group.
The contents of each of the above-mentioned commonly-assigned patent applications and PCT international applications is incorporated herein by reference.
Thus, there continues to be a need to provide additional technologies for forming polymeric prodrugs of therapeutic moieties. The present invention addresses this need.
SUMMARY OF THE INVENTION
In one aspect of the invention, compounds of Formula (I) are provided:
wherein:
E
1-4
are independently selected from the group consisting of hydrogen, C
1-6
alkyls, C
3-12
branched alkyls, C
3-8
cycloalkyls, C
1-6
substituted alkyls, C
3-8
substituted cycloalkyls, aryls, substituted aryls, aralkyls, C
1-6
heteroalkyls, substituted C
1-6
heteroalkyls, C
1-6
alkoxy, phenoxy, C
1-6
heteroalkoxy,
and at least one of E
1-4
includes a B moiety;
B is a leaving group, OH, a residue of a hydroxyl-containing moiety, a residue of an amine-containing moiety or
wherein E
5
is independently selected from the same group which defines E
1-4
;
E
1a-3a
are independently selected from the group consisting of hydrogen, C
1-6
alkyls, C
3-12
branched alkyls, C
3-8
cycloalkyls, C
1-6
substituted alkyls, C
3-8
substituted cycloalkyls, aryls, substituted aryls, aralkyls, C
1-6
heteroalkyls, substituted C
1-6
heteroalkyls, C
1-6
alkoxy, phenoxy, C
1-6
heteroalkoxy,
wherein B
1
is a leaving group, OH, a residue of a hydroxyl-containing moiety or a residue of an amine-containing moiety or
wherein E
6
is independently selected from the same group which defines E
1-4
;
wherein E
1b-3b
are independently selected from the group consisting of hydrogen, C
1-6
alkyls, C
3-12
branched alkyls, C
3-8
cycloalkyls, C
1-6
substituted alkyls, C
3-8
substituted cycloalkyls, aryls, substituted aryls, aralkyls, C
1-6
heteroalkyls, substituted C
1-6
heteroalkyls, C
1-6
alkoxy, phenoxy, C
1-6
heteroalkoxy,
wherein B
2
is a leaving group, OH, a residue of a hydroxyl-containing moiety or a residue of an amine-containing moiety;
G is a polymeric residue;
Y
1-3
, Y
2a-d
and Y
3a-d
are each independently O, S or NR
11a
M
1-4
, M
2a-2d
, M
3a-3d
, and M
4a-4d
are each independently O, S or NR
11b
;
M
5
and M
5a-d
are each independently X or Q,
wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y
3
) or C(═Y
3a-d
);
R
1-10
, R
1a-11a
, R
1b-11b
, R
1c-10c
and R
1d-10d
are each independently selected from the group consisting of hydrogen, C
1-6
alkyls, C
3-12
branched alkyls, C
3-8
cycloalkyls, C
1-6
substituted alkyls, C
3-8
substituted cycloalkyls, aryls, substituted aryls, aralkyls, C
1-6
heteroalkyls, substituted C
1-6
heteroalkyls, C
1-6
alkoxy, phenoxy and C
1-6
heteroalkoxy; and
a, b, c, d1-d6, e1-e6, f1-f6, g1-g6, h1-h6, i1-i6, j1-j6, k1-k6, l1-l6, m1-m6 are each independently zero or a positive integer.
In preferred aspects of the invention, the polymeric residue is also substituted on the distal portion with another branching group to provide compounds of the formula (II):
where all variables are as previously defined. Such bifunctional polymeric compounds allow the artisan to load anywhere from two up to sixteen, or more equivalents of a biologically active agent, e.g. drug or protein, etc., per polymer.
When B is a residue of a hydroxyl-containing moiety or an amine-containing moiety, each B is attached via a preferably hydrolyzable linkage which attaches to the polymer residue terminus.
Examples of hydroxyl-containing moieties for which one or more of improved aqueous solubility, decreased antigenicity, prodrug and/or controlled release delivery is desired include chemotherapeutic compound residues such as anti-fungal compounds, including hydroxyl-containing triazoles, hydroxyl-containing echinocandins, hydroxyl-containing pneumocandins, etc, anti-cancer compounds such as camptothecin, paclitaxel, etoposide, anti-cancer platinum compounds containing OH groups, floxuridine or podophyllotoxin.
Examples of amine-containing moieties for which one or more of improved aqueous solubility, decreased antigenicity, prodrug and/or controlled release delivery is desired include antimetabolites such as Ara-C or gemcitabine. In still further embodiments, other oncolytic agents, non
Choe Yun H.
Greenwald Richard B.
Carlson Karen Cochrane
Desai Anand U
Enzon Pharmaceuticals, Inc.
Muserlian, Lucas & Mercanti, LLP
LandOfFree
Terminally-branched polymeric linkers containing extension... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Terminally-branched polymeric linkers containing extension..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Terminally-branched polymeric linkers containing extension... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3270469